Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Passage BIO, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 102 | 110 | +8 |
| Shares | 43.7M | 43.0M | −761.7K (−1.7%) |
| Value | $277.7M | $133.2M | −$144.5M (−52.0%) |
New holders (24)
Institutions that held Passage BIO, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (16)
Institutions that held Passage BIO, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Frazier Management LLC | 5,009,219 | $31.8M |
| Jacobs Levy Equity Management, Inc | 90,787 | $576.0K |
| Nomura Holdings Inc | 57,381 | $364.0K |
| Trexquant Investment LP | 50,170 | $319.0K |
| ExodusPoint Capital Management, LP | 26,595 | $169.0K |
| Manufacturers Life Insurance Company, The | 21,524 | $137.0K |
| Walleye Capital LLC | 18,653 | $118.0K |
| HRT Financial LP | 15,481 | $98.0K |
| Alpine Global Management, LLC | 14,570 | $93.0K |
| MetLife Investment Management | 10,730 | $68.1K |
| Metropolitan Life Insurance Co | 3,294 | $20.9K |
| Parallel Advisors, LLC | 1,241 | $8.00K |
| Signaturefd, LLC | 395 | $3.00K |
| Lindbrook Capital, LLC | 500 | $3.00K |
| Koshinski Asset Management, Inc. | 300 | $1.91K |
| State of Wyoming | 6 | $0 |